Matthew J Sheetz

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. doi request reprint The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies
    Matthew J Sheetz
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Invest Ophthalmol Vis Sci 54:1750-7. 2013
  2. doi request reprint Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2)
    Matthew J Sheetz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Retina 31:1053-9. 2011

Detail Information

Publications2

  1. doi request reprint The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies
    Matthew J Sheetz
    Eli Lilly and Company, Indianapolis, IN 46285, USA
    Invest Ophthalmol Vis Sci 54:1750-7. 2013
    ..To assess the effect of ruboxistaurin (RBX) on vision loss through a prospectively defined combined analysis of two phase 3 trials (MBDL and MBCU)...
  2. doi request reprint Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2)
    Matthew J Sheetz
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA
    Retina 31:1053-9. 2011
    ..034). This study evaluates the primary end point of SMVL in a 2-year open-label extension (OLE) of the PKC-DRS2, which began a median of 466 days (range, 263-1,296 days) after the conclusion of PKC-DRS2...